Neuroscience Department

2019-22  Research Grant Award (603003) co-funded by the from the Muscular Dystrophy Association, USA (MDA) –CMT Association- entitled “A translatable gene therapy approach to treat CMT1X” ($276,430)- PI
2019-21 Research Grant Award “Development of gene silencing approach to treat CMT1A” – CMT Research Foundation ($99,000, PI).
2019-20  Funding by the CyprusSeeds Program for innovation ($50,000) (PI)- Gene Therapy for Inherited Neuropathies 
2019-21 Research Grant from the Charcot-Marie-Tooth Association (CMTA) “AAV mediated Gene Therapy for CMT4C” ($122,100 for 2 years)- PI
2020-25 Sponsored Research Agreement with Gene Therapy Company ($533,000) (PI), for translating gene therapy for CMT1X
2020-24  Funding by Association Piccolo Grande Guerriero Odv Italy- Research Project Gene therapy for HLD2 leukodystropy (€75,360) – PI
2021-22  Sponsored Research Agreement with Gene Therapy Company ($97,000) (PI)- for translating gene therapy for CMT4C
2021-23  Research Grant from the Charcot-Marie-Tooth Association (CMTA) “Schwann cell-targeted gene therapy approaches to treat CMT1A and other demyelinating neuropathies” ($38,500 for 18 months)- PI
2021-23  Research Grant from Industry ($182,360)- PI
2023-24  Research Grant Award (963041) from the Muscular Dystrophy Association, USA (MDA) “Ultrasound-induced access of therapeutics to peripheral nerves” ($50,000)- PI

2024-26  Research Grant from the European Leukodystrophy Association (ELA) (€172,400)- PI
2025-27  Sponsored Research Agreement with Gene Therapy Company ($240,120) (PI), for translating gene therapy for CMT1X